Multiple sclerosis: Where will we be in 2020?

Mount Sinai Journal of Medicine

Volumn 78, Issue 2, 2011, Pages 268-279

  Miller, Aaron E ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

genetics; immunology; MS; multiple sclerosis; therapeutics

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; CLADRIBINE; DACLIZUMAB; FINGOLIMOD; FUMARIC ACID; GLATIRAMER; INTERFERON BETA SERINE; LAQUINIMOD; MITOXANTRONE; NATALIZUMAB; OCRELIZUMAB; RITUXIMAB; TERIFLUNOMIDE; VITAMIN D;

ARTICLE; BRADYCARDIA; CHRONIC VEIN INSUFFICIENCY; DISEASE COURSE; DRUG APPROVAL; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; HUMAN; MULTIPLE SCLEROSIS; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE; PROGNOSIS; RELAPSE; RETINA MACULA EDEMA; RISK FACTOR;

ANTIBODIES, MONOCLONAL; FORECASTING; GENETIC RESEARCH; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MULTIPLE SCLEROSIS; PROGNOSIS; RESEARCH; SPINAL CORD; VENOUS INSUFFICIENCY; VITAMIN D;

EID: 79953017501     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.20242     Document Type: Article

References (45)

1. McDonald WI, Compston A, Edan G, et al,. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
2. Polman CH, Reingold SC, Edan G, et al,. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann Neurol 2005; 11: 840-846. (Pubitemid 41746873)
3. Montalban X, Tintoré M, Swanton J, et al,. (2010). MRI criteria for MS in patients with clinically isolated syndromes. Neurology 2010; 74: 427-434.
4. Lünemann JD, Münz C., Epstein-Barr virus and multiple sclerosis. Curr Neurol Neurosci Rep 2007; 7: 253-258. (Pubitemid 46831520)
5. Thacker EL, Mirzaei F, Ascherio A., Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol 2006; 59: 499-503. (Pubitemid 43358070)
6. Nielsen TR, Rostgaard K, Nielsen NM, et al,. Multiple sclerosis after infectious mononucleosis. Arch Neurol 2007; 64: 72-75. (Pubitemid 46072426)
7. Levin LI, Munger KL, Rubertone MV, et al,. Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 2005; 293: 2496-2500. (Pubitemid 40705731)
8. Pohl D, Krone B, Rostasy K, et al,. High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology 2006; 67: 2063-2065. (Pubitemid 44967394)
9. Ascherio A, Munger KL, Simon KC., Vitamin D and multiple sclerosis. Lancet Neurol 2010; 9: 599-612.
10. Pierrot-Deseilligny C, Souberbielle JC., Is hypovitaminosis D one of the environmental risk factors for multiple sclerosis? Brain 2010; 133 (part 7): 1869-1888.
11. Gorelik L, Lerner M, Bixler S, et al,. Anti-JC virus antibodies: implication for PML risk stratification. Ann Neurol 2010; 68: 295-303.
12. Vukusic S, Van Bockstael V, Gosselin S, et al,. Regional variations in the prevalence of multiple sclerosis in French farmers. J Neurol Neurosurg Psychiatry 2007; 78: 707-709. (Pubitemid 46998840)
13. Van der Mei IA, Ponsonby AL, Dwyer T, et al,. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. BMJ 2003; 327: 316.
14. Dean G, Yeo TW, Goris A, et al,. HLA-DRB1 and multiple sclerosis in Malta. Neurology 2008; 70: 101-105.
15. Grimaldi LM, Salemi G, Grimaldi G, et al,. High incidence and increasing prevalence of MS in Enna (Sicily), southern Italy. Neurology 2001; 57: 1891-1893. (Pubitemid 33096702)
16. Willer CJ, Dyment DA, Risch NJ, et al,. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc Natl Acad Sci U S A 2003; 100: 12877-12882. (Pubitemid 37339993)
17. Habek M, Brinar VV, Borovečki F., Genes associated with multiple sclerosis: 15 and counting. Expert Rev Mol Diagn 2010; 10: 857-861.
18. De Jager PL, Chibnik LB, Cui J, et al,. Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. Lancet Neurol 2009; 8: 1111-1119.
19. Sawcer S, Ban M, Wason J, et al,. What role for genetics in the prediction of multiple sclerosis? Ann Neurol 2010; 67: 3-10.
20. Langer-Gould A, Popat RA, Huang SM, et al,. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. Arch Neurol 2006; 63: 1686-1691. (Pubitemid 44925075)
21. Degenhardt A, Ramagopalan SV, Scalfari A, et al,. Clinical prognostic factors in multiple sclerosis: a natural history review. Nat Rev Neurol 2009; 5: 672-682.
22. Fisniku LK, Brex PA, Altmann DR, et al,. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008; 131 (part 3): 808-817. (Pubitemid 351294716)
23. Confavreux C, Vukusic S, Moreau T, et al,. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343: 1430-1438.
24. Polman CH, O'Connor PW, Havrdova E, et al,. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
25. Kleinschmidt-DeMasters BK, Tyler KL., Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353: 369-374. (Pubitemid 41132341)
26. Langer-Gould A, Atlas SW, Green AJ, et al,. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353: 375-381. (Pubitemid 41132342)
27. Gorelik L, Bixler S, Lerner M, et al,. Assessment of the incidence of anti-JCV antibodies in a cohort of natalizumab-treated patients with multiple sclerosis. Paper presented at: 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); October 13-16, 2010; Gothenburg, Sweden. Accessed November 21, 2010.
28. Cohen JA, Barkhof F, Comi G, et al,; TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-415.
29. Kappos L, Radue EW, O'Connor P, et al,; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401.
30. Giovannoni G, Comi G, Cook S, et al,. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010; 362: 416-426.
31. O'Connor P, Wolinsky J, Confavreux C, et al,; Teriflunomide Multiple Sclerosis Study Group. A placebo-controlled phase II trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis: clinical efficacy and safety outcomes. Paper presented at: 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); October 13-16, 2010; Gothenburg, Sweden. Accessed November 21, 2010.
32. Kappos L, Gold R, Miller D, et al,. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 372: 1463-1472.
33. Comi G, Pulizzi A, Rovaris M, et al,. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 371: 2085-2092. (Pubitemid 351842581)
34. Hauser SL, Waubant E, Arnold DL, et al,. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676-688. (Pubitemid 351240747)
35. Kappos L, Calabresi P, O'Connor P, et al,. Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis: results of a phase II randomised placebo-controlled multicentre trial. Paper presented at: 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); October 13-16, 2010; Gothenburg, Sweden. Accessed November 21, 2010.
36. Coles AJ, Compston DA, Selmaj KW, et al,; CAMMS223 Trial Investigators. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008; 359: 1786-1801.
37. Wynn D, Kaufman M, Montalban X, et al,. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta [published correction appears in Lancet Neurol 2010;9:759]. Lancet Neurol 2010; 9: 381-390.
38. Wolinsky JS, Narayana PA, O'Connor P, et al,. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007; 61: 14-24. (Pubitemid 46214240)
39. Hawker K, O'Connor P, Freedman MS, et al,; OLYMPUS Trial Group. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66: 460-471.
40. Zamboni P, Galeotti R, Menegatti E, et al,. Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2009; 80: 392-399.
41. Zamboni P, Galeotti R, Menegatti E, et al,. A prospective open-label study of endovascular treatment of chronic cerebrospinal venous insufficiency [published correction appears in J Vasc Surg 2010:51:1079]. J Vasc Surg 2009; 50: 1348-1358. e1-3.
42. MSRC comments on Stanford University reportedly halting CCSVI treatments after two serious adverse events. Medical News Today; March 10, 2010. Accessed November 21, 2010.
43. Ontario man dies after MS vein opening. Ontario, Canada: CBC News; November 18, 2010. Accessed November 21, 2010.
44. Doepp F, Paul F, Valdueza JM, et al,. No cerebrocervical venous congestion in patients with multiple sclerosis. Ann Neurol 2010; 68: 173-183.
45. Sundström P, WÃhlin A, Ambarki K, et al,. Venous and cerebrospinal fluid flow in multiple sclerosis: a case-control study. Ann Neurol 2010; 255-259.